Medical Care

Global Minimal Residual Disease (MRD) Testing Market Research Report 2025

The global market for Minimal Residual Disease (MRD) Testing was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Minimal Residual Disease (MRD) Testing is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Minimal Residual Disease (MRD) Testing is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Minimal Residual Disease (MRD) Testing in Specialty Clinics is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Minimal Residual Disease (MRD) Testing include Sysmex Corporation, Natera, Asuragen, Quest Diagnostics, Mission Bio, LabCorp, Guardant Health, NeoGenomics Laboratories, ARUP Laboratories, NeoGenomics , Inc, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Minimal Residual Disease (MRD) Testing, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Minimal Residual Disease (MRD) Testing.
The Minimal Residual Disease (MRD) Testing market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Minimal Residual Disease (MRD) Testing market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Minimal Residual Disease (MRD) Testing companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Sysmex Corporation
Natera
Asuragen
Quest Diagnostics
Mission Bio
LabCorp
Guardant Health
NeoGenomics Laboratories
ARUP Laboratories
NeoGenomics , Inc
Opko Health
Bio-Rad Laboratories
Segment by Type
Flow Cytometry
Polymerase Chain Reaction
Next-generation Sequencing
Liquid Biopsies
Segment by Application
Specialty Clinics
Hospitals
Research Institutions
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Minimal Residual Disease (MRD) Testing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Minimal Residual Disease (MRD) Testing Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Flow Cytometry
1.2.3 Polymerase Chain Reaction
1.2.4 Next-generation Sequencing
1.2.5 Liquid Biopsies
1.3 Market by Application
1.3.1 Global Minimal Residual Disease (MRD) Testing Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Specialty Clinics
1.3.3 Hospitals
1.3.4 Research Institutions
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Minimal Residual Disease (MRD) Testing Market Perspective (2020-2031)
2.2 Global Minimal Residual Disease (MRD) Testing Growth Trends by Region
2.2.1 Global Minimal Residual Disease (MRD) Testing Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Minimal Residual Disease (MRD) Testing Historic Market Size by Region (2020-2025)
2.2.3 Minimal Residual Disease (MRD) Testing Forecasted Market Size by Region (2026-2031)
2.3 Minimal Residual Disease (MRD) Testing Market Dynamics
2.3.1 Minimal Residual Disease (MRD) Testing Industry Trends
2.3.2 Minimal Residual Disease (MRD) Testing Market Drivers
2.3.3 Minimal Residual Disease (MRD) Testing Market Challenges
2.3.4 Minimal Residual Disease (MRD) Testing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Minimal Residual Disease (MRD) Testing Players by Revenue
3.1.1 Global Top Minimal Residual Disease (MRD) Testing Players by Revenue (2020-2025)
3.1.2 Global Minimal Residual Disease (MRD) Testing Revenue Market Share by Players (2020-2025)
3.2 Global Minimal Residual Disease (MRD) Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Minimal Residual Disease (MRD) Testing Revenue
3.4 Global Minimal Residual Disease (MRD) Testing Market Concentration Ratio
3.4.1 Global Minimal Residual Disease (MRD) Testing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Minimal Residual Disease (MRD) Testing Revenue in 2024
3.5 Global Key Players of Minimal Residual Disease (MRD) Testing Head office and Area Served
3.6 Global Key Players of Minimal Residual Disease (MRD) Testing, Product and Application
3.7 Global Key Players of Minimal Residual Disease (MRD) Testing, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Minimal Residual Disease (MRD) Testing Breakdown Data by Type
4.1 Global Minimal Residual Disease (MRD) Testing Historic Market Size by Type (2020-2025)
4.2 Global Minimal Residual Disease (MRD) Testing Forecasted Market Size by Type (2026-2031)
5 Minimal Residual Disease (MRD) Testing Breakdown Data by Application
5.1 Global Minimal Residual Disease (MRD) Testing Historic Market Size by Application (2020-2025)
5.2 Global Minimal Residual Disease (MRD) Testing Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Minimal Residual Disease (MRD) Testing Market Size (2020-2031)
6.2 North America Minimal Residual Disease (MRD) Testing Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Minimal Residual Disease (MRD) Testing Market Size by Country (2020-2025)
6.4 North America Minimal Residual Disease (MRD) Testing Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Minimal Residual Disease (MRD) Testing Market Size (2020-2031)
7.2 Europe Minimal Residual Disease (MRD) Testing Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Minimal Residual Disease (MRD) Testing Market Size by Country (2020-2025)
7.4 Europe Minimal Residual Disease (MRD) Testing Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Minimal Residual Disease (MRD) Testing Market Size (2020-2031)
8.2 Asia-Pacific Minimal Residual Disease (MRD) Testing Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Minimal Residual Disease (MRD) Testing Market Size by Region (2020-2025)
8.4 Asia-Pacific Minimal Residual Disease (MRD) Testing Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Minimal Residual Disease (MRD) Testing Market Size (2020-2031)
9.2 Latin America Minimal Residual Disease (MRD) Testing Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Minimal Residual Disease (MRD) Testing Market Size by Country (2020-2025)
9.4 Latin America Minimal Residual Disease (MRD) Testing Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Minimal Residual Disease (MRD) Testing Market Size (2020-2031)
10.2 Middle East & Africa Minimal Residual Disease (MRD) Testing Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Minimal Residual Disease (MRD) Testing Market Size by Country (2020-2025)
10.4 Middle East & Africa Minimal Residual Disease (MRD) Testing Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sysmex Corporation
11.1.1 Sysmex Corporation Company Details
11.1.2 Sysmex Corporation Business Overview
11.1.3 Sysmex Corporation Minimal Residual Disease (MRD) Testing Introduction
11.1.4 Sysmex Corporation Revenue in Minimal Residual Disease (MRD) Testing Business (2020-2025)
11.1.5 Sysmex Corporation Recent Development
11.2 Natera
11.2.1 Natera Company Details
11.2.2 Natera Business Overview
11.2.3 Natera Minimal Residual Disease (MRD) Testing Introduction
11.2.4 Natera Revenue in Minimal Residual Disease (MRD) Testing Business (2020-2025)
11.2.5 Natera Recent Development
11.3 Asuragen
11.3.1 Asuragen Company Details
11.3.2 Asuragen Business Overview
11.3.3 Asuragen Minimal Residual Disease (MRD) Testing Introduction
11.3.4 Asuragen Revenue in Minimal Residual Disease (MRD) Testing Business (2020-2025)
11.3.5 Asuragen Recent Development
11.4 Quest Diagnostics
11.4.1 Quest Diagnostics Company Details
11.4.2 Quest Diagnostics Business Overview
11.4.3 Quest Diagnostics Minimal Residual Disease (MRD) Testing Introduction
11.4.4 Quest Diagnostics Revenue in Minimal Residual Disease (MRD) Testing Business (2020-2025)
11.4.5 Quest Diagnostics Recent Development
11.5 Mission Bio
11.5.1 Mission Bio Company Details
11.5.2 Mission Bio Business Overview
11.5.3 Mission Bio Minimal Residual Disease (MRD) Testing Introduction
11.5.4 Mission Bio Revenue in Minimal Residual Disease (MRD) Testing Business (2020-2025)
11.5.5 Mission Bio Recent Development
11.6 LabCorp
11.6.1 LabCorp Company Details
11.6.2 LabCorp Business Overview
11.6.3 LabCorp Minimal Residual Disease (MRD) Testing Introduction
11.6.4 LabCorp Revenue in Minimal Residual Disease (MRD) Testing Business (2020-2025)
11.6.5 LabCorp Recent Development
11.7 Guardant Health
11.7.1 Guardant Health Company Details
11.7.2 Guardant Health Business Overview
11.7.3 Guardant Health Minimal Residual Disease (MRD) Testing Introduction
11.7.4 Guardant Health Revenue in Minimal Residual Disease (MRD) Testing Business (2020-2025)
11.7.5 Guardant Health Recent Development
11.8 NeoGenomics Laboratories
11.8.1 NeoGenomics Laboratories Company Details
11.8.2 NeoGenomics Laboratories Business Overview
11.8.3 NeoGenomics Laboratories Minimal Residual Disease (MRD) Testing Introduction
11.8.4 NeoGenomics Laboratories Revenue in Minimal Residual Disease (MRD) Testing Business (2020-2025)
11.8.5 NeoGenomics Laboratories Recent Development
11.9 ARUP Laboratories
11.9.1 ARUP Laboratories Company Details
11.9.2 ARUP Laboratories Business Overview
11.9.3 ARUP Laboratories Minimal Residual Disease (MRD) Testing Introduction
11.9.4 ARUP Laboratories Revenue in Minimal Residual Disease (MRD) Testing Business (2020-2025)
11.9.5 ARUP Laboratories Recent Development
11.10 NeoGenomics , Inc
11.10.1 NeoGenomics , Inc Company Details
11.10.2 NeoGenomics , Inc Business Overview
11.10.3 NeoGenomics , Inc Minimal Residual Disease (MRD) Testing Introduction
11.10.4 NeoGenomics , Inc Revenue in Minimal Residual Disease (MRD) Testing Business (2020-2025)
11.10.5 NeoGenomics , Inc Recent Development
11.11 Opko Health
11.11.1 Opko Health Company Details
11.11.2 Opko Health Business Overview
11.11.3 Opko Health Minimal Residual Disease (MRD) Testing Introduction
11.11.4 Opko Health Revenue in Minimal Residual Disease (MRD) Testing Business (2020-2025)
11.11.5 Opko Health Recent Development
11.12 Bio-Rad Laboratories
11.12.1 Bio-Rad Laboratories Company Details
11.12.2 Bio-Rad Laboratories Business Overview
11.12.3 Bio-Rad Laboratories Minimal Residual Disease (MRD) Testing Introduction
11.12.4 Bio-Rad Laboratories Revenue in Minimal Residual Disease (MRD) Testing Business (2020-2025)
11.12.5 Bio-Rad Laboratories Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Minimal Residual Disease (MRD) Testing Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Flow Cytometry
Table 3. Key Players of Polymerase Chain Reaction
Table 4. Key Players of Next-generation Sequencing
Table 5. Key Players of Liquid Biopsies
Table 6. Global Minimal Residual Disease (MRD) Testing Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Minimal Residual Disease (MRD) Testing Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Minimal Residual Disease (MRD) Testing Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Minimal Residual Disease (MRD) Testing Market Share by Region (2020-2025)
Table 10. Global Minimal Residual Disease (MRD) Testing Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Minimal Residual Disease (MRD) Testing Market Share by Region (2026-2031)
Table 12. Minimal Residual Disease (MRD) Testing Market Trends
Table 13. Minimal Residual Disease (MRD) Testing Market Drivers
Table 14. Minimal Residual Disease (MRD) Testing Market Challenges
Table 15. Minimal Residual Disease (MRD) Testing Market Restraints
Table 16. Global Minimal Residual Disease (MRD) Testing Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Minimal Residual Disease (MRD) Testing Market Share by Players (2020-2025)
Table 18. Global Top Minimal Residual Disease (MRD) Testing Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Minimal Residual Disease (MRD) Testing as of 2024)
Table 19. Ranking of Global Top Minimal Residual Disease (MRD) Testing Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Minimal Residual Disease (MRD) Testing Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Minimal Residual Disease (MRD) Testing, Headquarters and Area Served
Table 22. Global Key Players of Minimal Residual Disease (MRD) Testing, Product and Application
Table 23. Global Key Players of Minimal Residual Disease (MRD) Testing, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Minimal Residual Disease (MRD) Testing Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Minimal Residual Disease (MRD) Testing Revenue Market Share by Type (2020-2025)
Table 27. Global Minimal Residual Disease (MRD) Testing Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Minimal Residual Disease (MRD) Testing Revenue Market Share by Type (2026-2031)
Table 29. Global Minimal Residual Disease (MRD) Testing Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Minimal Residual Disease (MRD) Testing Revenue Market Share by Application (2020-2025)
Table 31. Global Minimal Residual Disease (MRD) Testing Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Minimal Residual Disease (MRD) Testing Revenue Market Share by Application (2026-2031)
Table 33. North America Minimal Residual Disease (MRD) Testing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Minimal Residual Disease (MRD) Testing Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Minimal Residual Disease (MRD) Testing Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Minimal Residual Disease (MRD) Testing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Minimal Residual Disease (MRD) Testing Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Minimal Residual Disease (MRD) Testing Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Minimal Residual Disease (MRD) Testing Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Minimal Residual Disease (MRD) Testing Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Minimal Residual Disease (MRD) Testing Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Minimal Residual Disease (MRD) Testing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Minimal Residual Disease (MRD) Testing Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Minimal Residual Disease (MRD) Testing Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Minimal Residual Disease (MRD) Testing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Minimal Residual Disease (MRD) Testing Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Minimal Residual Disease (MRD) Testing Market Size by Country (2026-2031) & (US$ Million)
Table 48. Sysmex Corporation Company Details
Table 49. Sysmex Corporation Business Overview
Table 50. Sysmex Corporation Minimal Residual Disease (MRD) Testing Product
Table 51. Sysmex Corporation Revenue in Minimal Residual Disease (MRD) Testing Business (2020-2025) & (US$ Million)
Table 52. Sysmex Corporation Recent Development
Table 53. Natera Company Details
Table 54. Natera Business Overview
Table 55. Natera Minimal Residual Disease (MRD) Testing Product
Table 56. Natera Revenue in Minimal Residual Disease (MRD) Testing Business (2020-2025) & (US$ Million)
Table 57. Natera Recent Development
Table 58. Asuragen Company Details
Table 59. Asuragen Business Overview
Table 60. Asuragen Minimal Residual Disease (MRD) Testing Product
Table 61. Asuragen Revenue in Minimal Residual Disease (MRD) Testing Business (2020-2025) & (US$ Million)
Table 62. Asuragen Recent Development
Table 63. Quest Diagnostics Company Details
Table 64. Quest Diagnostics Business Overview
Table 65. Quest Diagnostics Minimal Residual Disease (MRD) Testing Product
Table 66. Quest Diagnostics Revenue in Minimal Residual Disease (MRD) Testing Business (2020-2025) & (US$ Million)
Table 67. Quest Diagnostics Recent Development
Table 68. Mission Bio Company Details
Table 69. Mission Bio Business Overview
Table 70. Mission Bio Minimal Residual Disease (MRD) Testing Product
Table 71. Mission Bio Revenue in Minimal Residual Disease (MRD) Testing Business (2020-2025) & (US$ Million)
Table 72. Mission Bio Recent Development
Table 73. LabCorp Company Details
Table 74. LabCorp Business Overview
Table 75. LabCorp Minimal Residual Disease (MRD) Testing Product
Table 76. LabCorp Revenue in Minimal Residual Disease (MRD) Testing Business (2020-2025) & (US$ Million)
Table 77. LabCorp Recent Development
Table 78. Guardant Health Company Details
Table 79. Guardant Health Business Overview
Table 80. Guardant Health Minimal Residual Disease (MRD) Testing Product
Table 81. Guardant Health Revenue in Minimal Residual Disease (MRD) Testing Business (2020-2025) & (US$ Million)
Table 82. Guardant Health Recent Development
Table 83. NeoGenomics Laboratories Company Details
Table 84. NeoGenomics Laboratories Business Overview
Table 85. NeoGenomics Laboratories Minimal Residual Disease (MRD) Testing Product
Table 86. NeoGenomics Laboratories Revenue in Minimal Residual Disease (MRD) Testing Business (2020-2025) & (US$ Million)
Table 87. NeoGenomics Laboratories Recent Development
Table 88. ARUP Laboratories Company Details
Table 89. ARUP Laboratories Business Overview
Table 90. ARUP Laboratories Minimal Residual Disease (MRD) Testing Product
Table 91. ARUP Laboratories Revenue in Minimal Residual Disease (MRD) Testing Business (2020-2025) & (US$ Million)
Table 92. ARUP Laboratories Recent Development
Table 93. NeoGenomics , Inc Company Details
Table 94. NeoGenomics , Inc Business Overview
Table 95. NeoGenomics , Inc Minimal Residual Disease (MRD) Testing Product
Table 96. NeoGenomics , Inc Revenue in Minimal Residual Disease (MRD) Testing Business (2020-2025) & (US$ Million)
Table 97. NeoGenomics , Inc Recent Development
Table 98. Opko Health Company Details
Table 99. Opko Health Business Overview
Table 100. Opko Health Minimal Residual Disease (MRD) Testing Product
Table 101. Opko Health Revenue in Minimal Residual Disease (MRD) Testing Business (2020-2025) & (US$ Million)
Table 102. Opko Health Recent Development
Table 103. Bio-Rad Laboratories Company Details
Table 104. Bio-Rad Laboratories Business Overview
Table 105. Bio-Rad Laboratories Minimal Residual Disease (MRD) Testing Product
Table 106. Bio-Rad Laboratories Revenue in Minimal Residual Disease (MRD) Testing Business (2020-2025) & (US$ Million)
Table 107. Bio-Rad Laboratories Recent Development
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
Table 111. Authors List of This Report


List of Figures
Figure 1. Minimal Residual Disease (MRD) Testing Picture
Figure 2. Global Minimal Residual Disease (MRD) Testing Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Minimal Residual Disease (MRD) Testing Market Share by Type: 2024 VS 2031
Figure 4. Flow Cytometry Features
Figure 5. Polymerase Chain Reaction Features
Figure 6. Next-generation Sequencing Features
Figure 7. Liquid Biopsies Features
Figure 8. Global Minimal Residual Disease (MRD) Testing Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Minimal Residual Disease (MRD) Testing Market Share by Application: 2024 VS 2031
Figure 10. Specialty Clinics Case Studies
Figure 11. Hospitals Case Studies
Figure 12. Research Institutions Case Studies
Figure 13. Minimal Residual Disease (MRD) Testing Report Years Considered
Figure 14. Global Minimal Residual Disease (MRD) Testing Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 15. Global Minimal Residual Disease (MRD) Testing Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Minimal Residual Disease (MRD) Testing Market Share by Region: 2024 VS 2031
Figure 17. Global Minimal Residual Disease (MRD) Testing Market Share by Players in 2024
Figure 18. Global Top Minimal Residual Disease (MRD) Testing Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Minimal Residual Disease (MRD) Testing as of 2024)
Figure 19. The Top 10 and 5 Players Market Share by Minimal Residual Disease (MRD) Testing Revenue in 2024
Figure 20. North America Minimal Residual Disease (MRD) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. North America Minimal Residual Disease (MRD) Testing Market Share by Country (2020-2031)
Figure 22. United States Minimal Residual Disease (MRD) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Canada Minimal Residual Disease (MRD) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Minimal Residual Disease (MRD) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Minimal Residual Disease (MRD) Testing Market Share by Country (2020-2031)
Figure 26. Germany Minimal Residual Disease (MRD) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. France Minimal Residual Disease (MRD) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. U.K. Minimal Residual Disease (MRD) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Italy Minimal Residual Disease (MRD) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Russia Minimal Residual Disease (MRD) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Nordic Countries Minimal Residual Disease (MRD) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Minimal Residual Disease (MRD) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Minimal Residual Disease (MRD) Testing Market Share by Region (2020-2031)
Figure 34. China Minimal Residual Disease (MRD) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Japan Minimal Residual Disease (MRD) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. South Korea Minimal Residual Disease (MRD) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Southeast Asia Minimal Residual Disease (MRD) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. India Minimal Residual Disease (MRD) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Australia Minimal Residual Disease (MRD) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Minimal Residual Disease (MRD) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Minimal Residual Disease (MRD) Testing Market Share by Country (2020-2031)
Figure 42. Mexico Minimal Residual Disease (MRD) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Brazil Minimal Residual Disease (MRD) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Minimal Residual Disease (MRD) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Minimal Residual Disease (MRD) Testing Market Share by Country (2020-2031)
Figure 46. Turkey Minimal Residual Disease (MRD) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Saudi Arabia Minimal Residual Disease (MRD) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. UAE Minimal Residual Disease (MRD) Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Sysmex Corporation Revenue Growth Rate in Minimal Residual Disease (MRD) Testing Business (2020-2025)
Figure 50. Natera Revenue Growth Rate in Minimal Residual Disease (MRD) Testing Business (2020-2025)
Figure 51. Asuragen Revenue Growth Rate in Minimal Residual Disease (MRD) Testing Business (2020-2025)
Figure 52. Quest Diagnostics Revenue Growth Rate in Minimal Residual Disease (MRD) Testing Business (2020-2025)
Figure 53. Mission Bio Revenue Growth Rate in Minimal Residual Disease (MRD) Testing Business (2020-2025)
Figure 54. LabCorp Revenue Growth Rate in Minimal Residual Disease (MRD) Testing Business (2020-2025)
Figure 55. Guardant Health Revenue Growth Rate in Minimal Residual Disease (MRD) Testing Business (2020-2025)
Figure 56. NeoGenomics Laboratories Revenue Growth Rate in Minimal Residual Disease (MRD) Testing Business (2020-2025)
Figure 57. ARUP Laboratories Revenue Growth Rate in Minimal Residual Disease (MRD) Testing Business (2020-2025)
Figure 58. NeoGenomics , Inc Revenue Growth Rate in Minimal Residual Disease (MRD) Testing Business (2020-2025)
Figure 59. Opko Health Revenue Growth Rate in Minimal Residual Disease (MRD) Testing Business (2020-2025)
Figure 60. Bio-Rad Laboratories Revenue Growth Rate in Minimal Residual Disease (MRD) Testing Business (2020-2025)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies